Anti-ERCC5 / Excision repair cross-complementation group 5

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. ERCC5 antibody detects Excision repair cross-complementation group 5 protein, a structure-specific endonuclease essential for nucleotide excision repair (NER). Also known as Xeroderma pigmentosum group G protein (XPG), ERCC5 catalyzes 3' incision at sites of DNA damage, removing bulky lesions such as ultraviolet-induced pyrimidine dimers. The ERCC5 antibody is widely used in DNA repair, cancer, and dermatological research to study genome stability, DNA damage responses, and repair-deficient disorders.ERCC5 is encoded by the ERCC5 gene located on human chromosome 13q33.1. The protein is approximately 118 kilodaltons in size and belongs to the XPG/RAD2 family of structure-specific nucleases. It contains conserved N- and I-domains forming the catalytic core, as well as C-terminal regions mediating interactions with transcription and repair factors such as TFIIH and PCNA. Through these interactions, ERCC5 coordinates incision with repair synthesis during the NER process.The ERCC5 antibody typically detects a strong nuclear band near 133 kilodaltons by western blot. Immunofluorescence reveals nuclear localization, often enriched at DNA damage foci following UV or oxidative stress exposure. Functional studies demonstrate that ERCC5 excises damaged DNA downstream of the lesion, allowing DNA polymerases to resynthesize the correct strand. Mutations in ERCC5 cause Xeroderma pigmentosum complementation group G (XP-G) and Cockayne syndrome, conditions characterized by UV hypersensitivity, neurological abnormalities, and premature aging.Beyond its canonical repair function, ERCC5 also contributes to transcription-coupled repair and RNA polymerase II-mediated gene expression. It participates in DNA replication stress responses and protects replication forks from collapse under genotoxic stress. Dysregulation or reduced expression of ERCC5 has been linked to increased cancer susceptibility, particularly skin, liver, and lung cancers. NSJ Bioreagents offers a validated ERCC5 antibody optimized for western blot, immunohistochemistry, and DNA damage studies, providing researchers with a reliable tool for analyzing DNA repair mechanisms, NER efficiency, and genome protection pathways.